Background Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We present findings on treatment patterns and their associated survival outcomes in patients with stage III NSCLC from the Egypt subset of the KINDLE global real-world study conducted across countries from Asia, Middle East, Africa, and Latin America. Method Retrospective data from the Egypt subset (21 centers) of adult patients diagnosed with stage III NSCLC between January 2013 and December 2017 were analyzed. Descriptive and inferential statistics summarized treatment modalities, progression-free survival (PFS), and overall survival (OS). Results Of 421 patients enrolled (median age: 59.0 years), 77.9% were males, 53.5% had stage IIIA disease, 60.8% had adenocarcinoma, 78.4% had an unresectable disease, and 81.5% had Eastern Cooperative Oncology Group performance status ⩽1. Overall, chemotherapy alone (40.4%) was predominantly used in the initial line, whereas definite radiotherapy was used in only 5.0% of patients. In resectable patients, chemotherapy plus surgery (33.8%), surgery alone (20.6%), or other surgery (20.6%) were the top three modalities used in initial line of treatment. Chemotherapy alone was most preferred (48.8%) in unresectable patients, followed by sequential chemoradiotherapy (CRT) (17.6%) and concurrent CRT (9.3%). The overall median PFS was 10.3 months [95% confidence interval (CI), 9.43-12.02], whereas the median OS was 18.5 months (95% CI, 16.46-21.88). Overall, female gender, adenocarcinoma histology, and radical therapy as surgery or CRT predicted significantly longer OS (all p < 0.05). Conclusion KINDLE-Egypt cohort revealed wide heterogeneities in the treatment patterns of stage III NSCLC. Although deemed resectable, few patients did not undergo surgery, probably due to high smoking rates leading to poor lung function. Lower survival outcomes than other published real-world studies highlight the need for timely approval and availability of novel targeted and immunotherapies to enhance patient outcomes. Trial registration NCT03725475.

中文翻译：

---

III 期非小细胞肺癌患者的真实治疗模式和临床结果：KINDLE-Egypt 队列的结果。

背景 III 期非小细胞肺癌 (NSCLC) 具有高度异质性，需要多模式治疗策略才能实现最佳管理。我们介绍了 KINDLE 全球真实世界研究埃及子集的 III 期 NSCLC 患者的治疗模式及其相关生存结果的研究结果，该研究在亚洲、中东、非洲和拉丁美洲各国进行。方法 对 2013 年 1 月至 2017 年 12 月期间埃及诊断为 III 期 NSCLC 的成年患者的回顾性数据进行分析。描述性和推论性统计总结了治疗方式、无进展生存期 (PFS) 和总生存期 (OS)。结果 入组的 421 名患者（中位年龄：59.0 岁）中，77.9% 为男性，53.5% 为 IIIA 期疾病，60.8% 为腺癌，78.4% 为不可切除疾病，81.5% 为东部肿瘤合作组表现状态⩽1。总体而言，初始治疗主要使用单纯化疗（40.4%），而只有 5.0% 的患者使用明确的放疗。在可切除的患者中，化疗加手术（33.8%）、单独手术（20.6%）或其他手术（20.6%）是初始治疗中使用最多的三种方式。对于无法切除的患者，单独化疗是首选（48.8%），其次是序贯放化疗（CRT）（17.6%）和同步放化疗（9.3%）。总体中位 PFS 为 10.3 个月 [95% 置信区间 (CI)，9.43-12.02]，中位 OS 为 18.5 个月（95% CI，16.46-21.88）。总体而言，女性、腺癌组织学以及手术或 CRT 等根治性治疗可预测 OS 显着延长（所有 p < 0.05）。结论 KINDLE-Egypt 队列揭示了 III 期 NSCLC 治疗模式的广泛异质性。尽管被认为可以切除，但很少有患者没有接受手术，这可能是由于高吸烟率导致肺功能较差。与其他已发表的现实世界研究相比，生存结果较低，这凸显了需要及时批准和提供新型靶向和免疫疗法，以提高患者的治疗效果。试用注册NCT03725475。